MGMT and central nervous system cancer: Much scientific research combines GII and GIII as low-grade gliomas, while fewer studies have investigated the difference between GII and GIII, such as differences in survival outcome, key drivers of survival, and biomarkers, etc. The various clinical biomarkers currently used, such as O6-methylguanine-DNA methyltransferase (MGMT), have insufficient sensitivity, and specificity when it comes to gliomas (Wick et al., 2014).